SNMMI NEWSLINE

23N Joint NIBIB/NCI/SNMMI Workshop on Directly Imaging Targeted Radionuclide Therapy Isotopes
I. George Zubal and Jacek Capala

26N DOE and HHS Certify Sufficient 99Mo Supplies

26N FDA Approves New 68Ga Kit for Prostate Cancer PET

27N SNMMI Leadership Update: SNMMI to Host Summits on Artificial Intelligence and Patient Access
Richard L. Wahl

DISCUSSIONS WITH LEADERS

169 A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann
Silke Gillessen, Johannes Czernin, and Ken Herrmann

THE STATE OF THE ART

172 A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies
Fanny Orlhac, Jakoba J. Eertink, Anne-Ségolène Cottereau, Josée M. Zijlstra, Catherine Thieblemont, Michel Meignan, Ronald Boellaard, and Irène Buvat

HOT TOPICS

180 Is It Too Soon to Know When It’s LATE?
Angela C. Rieger and Daniel H.S. Silverman

FOCUS ON MOLECULAR IMAGING

183 Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox
Chao Li, Chaozhe Han, Shao Duan, Ping Li, Izrat S. Alam, and Zunyu Xiao

STANDARD OF CARE

189 Management of Differentiated Thyroid Cancer: The Standard of Care
Anca M. Avram, Katherine Zukotynski, Helen Ruth Nadel, and Luca Giovanella

EDITORIAL

196 Managing a High-Specific-Activity Iobenguane Therapy Clinic: From Operations to Reimbursement
Sophia R. O’Brien and Daniel A. Pryma

ONCOLOGY

Clinical

199 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma

205 131I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors
Ying Zhang, Juergen Kupferschlaeger, Peter Lang, Gerald Reischl, Rupert J. Handgretinger, Christian la Fougère, and Helmut Dittmann

THERANOSTICS

Clinical

212 Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPi PET/CT
Xiao Jin, Masanao Wei, Shuaiang Wang, Guochang Wang, Yumei Lai, Yunfei Shi, Yan Zhang, Zhi Yang, and Xuejuan Wang

218 Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study

226 Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?

233 aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer
Nicholas Nickols, Aseem Anand, Kerstin Johnsson, Johan Brynolfsson, Pablo Borrelli, Neil Parikh, Jesus Juarez, Lidaafari, Mattias Eiber, and Matthew Rettig

240 Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)

248 Brief Communication. The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Liang Dong, Yun Su, Yinjie Zhu, Mark C. Markowski, Mei Xin, Michael A. Gorin, Bajun Dong, Jiahua Pan, Martin G. Pomper, Jianjun Liu, et al.
253 Kidney Doses in $^{177}$Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowshita, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer, and Juri Ruf

Basic

259 *FEATURED BASIC SCIENCE ARTICLE.* An Improved $^{211}$At-Labeled Agent for PSMA-Targeted α-Therapy
Ronnie C. Mease, Choong Mo Kang, Vivek Kumar, Sangeeta Ray Banerjee, Il Minn, Mary Brummet, Kathleen L. Gabrielson, Yutian Feng, Andrew Park, Ana P. Kiess, et al.

Infectious Disease

Clinical

268 *INVITED PERSPECTIVE.* Imaging in Post-COVID Lung Disease: Does $^{18}$F-FDG PET/CT Have the Key?
Olivier Gheysens, Leila Belkhir, and Francois Jamar

270 *BRIEF COMMUNICATION.* Evolution of $^{18}$F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation

Clinical

274 Incidental Findings Suggestive of COVID-19 Pneumonia in Oncologic Patients Undergoing $^{18}$F-FDG PET/CT Studies: Association Between Metabolic and Structural Lung Changes
Cristina Gamda Wakfe-Corieh, Federico Ferrando-Castagnetto, Alba Maria Blanes Garcia, Marta Garcia Garcia-Esquinas, Aida Ortega Candil, Cristina Rodriguez Rey, Maria Nieves Cabrera-Martin, Ana Delgado Cano, and Jose Luis Carreras Delgado

Cardiovascular

Clinical

280 Comparing Semiquantitative and Qualitative Methods of Vascular $^{18}$F-FDG PET Activity Measurement in Large-Vessel Vasculitis
Himanshu R. Dashora, Joel S. Rosenblum, Kaitlin A. Quinn, Hugh Alessi, Elaine Novakovitch, Babak Saboury, Mark A. Ahlman, and Peter C. Grayson

Neurology

Clinical

287 Dynamic Amyloid PET: Relationships to $^{18}$F-Flortaucipir Tau PET Measures
Fabio Raman, Yu-Hua Dean Fang, Sameera Grandhi, Charles F. Murchison, Richard E. Kennedy, John C. Morris, Parinaz Massoumzadeh, Tammie Benzinger, Erik D. Roberson, and Jonathan McConathy

Basic

294 Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots
Javad Khodaii, Mostafa Araj-Khodaei, Manouchehr S. Vafaee, Dean F. Wong, and Albert Gjedde

302 $^{11}$C-PiB and $^{124}$I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention
Silvio R. Meier, Dag Sehlin, Sahar Roshanbin, Victoria Lim Falk, Takashi Saito, Takaomi C. Saito, Ulf Neumann, Johanna Rokka, Jonas Eriksson, and Stina Syvanen

Endocrinology

Clinical

310 *FEATURED ARTICLE OF THE MONTH.* $^{68}$Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism

Special Contribution

Michael G. Stabin, Richard E. Wendt, and Glenn D. Flux

Letters to the Editor

323 Commercially Competitive Vendor-Agnostic Image Reconstruction Could Be a Leap Forward for PET Harmonization
Adam L. Kesner

324 A VISION of ALSYMPCA
Paulo Schiavom Duarte

324 Reply: A VISION of ALSYMPCA
Oliver Sartor

325 On Semiquantitative Methods for Assessing Vascular $^{18}$F-FDG PET Activity in Large-Vessel Vasculitis
Eric Laffon and Roger Marthan

326 Reply: On Semiquantitative Methods for Assessing Vascular $^{18}$F-FDG PET Activity in Large-Vessel Vasculitis
Mark A. Ahlman, Roberto Maass-Morenco, and Peter C. Grayson

Departments

10A This Month in JNM
19A Recruitment
252 Erratum